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Purpose of the study
Atazanavir (ATV) is administered at the usual adult dose
of 300 mg with 100 mg of ritonavir (RTV) once a day
(boosted). However, 400 mg once a day (unboosted) is
also used in some settings. ATV plasma concentrations are
influenced by efflux transporters, influx transporters and
metabolism enzymes. The expression of many of these
proteins is regulated by nuclear receptors such as PXR.
Recently polymorphisms in the regulatory region of the
PXR gene have been reported to influence its expression
and the activity of downstream genes, such as CYP3A4
and ABCB1. The aim of this study was to investigate
whether polymorphisms in PXR influence trough concen-
trations (Ctrough) of boosted or unboosted ATV.
Methods
Patients were recruited in Torino, Italy, or from the Liver-
pool TDM registry, UK. Ethics committee approval was
obtained for genotyping. Respective totals of 110 patients
receiving unboosted ATV and 265 patients receiving
boosted ATV as part of their antiretroviral therapy were
included in this study. ATV plasma concentrations were
quantified using validated LC-MS or HPLC-UV methods.
Genotyping was conducted by real time PCR based allelic
discrimination using standard methodology. Statistical
analysis was conducted by Mann-Whitney or Spearman
Rank to assess the effects of weight, age, gender, tenofovir
(TDF) administration and genotype on ATV Ctrough.
Summary of results
No associations between patient demographics or TDF co-
administration were observed with either unboosted or
boosted ATV Ctrough. However, unboosted Ctrough was
lower for individuals characterised by PXR 63396 T
homozygosity compared to the other two groups (CC and
CT), 66 (IQR, 36–90) ng/mL vs. 161 (IQR, 55–266) ng/
mL (p = 0.0001). Similarly, boosted Ctrough concentra-
tions were lower in patients with PXR 63396 T homozy-
gosity compared to the other two groups (CC and CT),
458 (IQR, 283–838) ng/mL vs. 679 (IQR, 383–1051) ng/
mL (p = 0.02).
Conclusion
Homozygosity for PXR 63396 T was strongly correlated
with ATV Ctrough, which suggests that PXR is important
in the regulation of disposition of this drug. The impact of
63396 C>T was more marked for unboosted ATV, presum-
ably due to inhibition of CYP3A4 and ABCB1 by RTV in
the boosted regimen. Further studies are now required to
confirm this association, prior to prospective studies to
define its clinical value for individualisation of ATV ther-
apy.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P233 doi:10.1186/1758-2652-11-S1-P233
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P233
© 2008 Siccardi et al; licensee BioMed Central Ltd. 
